2. Academic Validation
  3. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity

Pharmacologic modulation of RNA splicing enhances anti-tumor immunity

  • Cell. 2021 Jul 22;184(15):4032-4047.e31. doi: 10.1016/j.cell.2021.05.038.
Sydney X Lu 1,  Emma De Neef 2,  James D Thomas 3,  Erich Sabio 4,  Benoit Rousseau 5,  Mathieu Gigoux 6,  David A Knorr 5,  Benjamin Greenbaum 7,  Yuval Elhanati 7,  Simon J Hogg 8,  Andrew Chow 9,  Arnab Ghosh 9,  Abigail Xie 10,  Dmitriy Zamarin 9,  Daniel Cui 8,  Caroline Erickson 8,  Michael Singer 8,  Hana Cho 8,  Eric Wang 8,  Bin Lu 8,  Benjamin H Durham 8,  Harshal Shah 8,  Diego Chowell 11,  Austin M Gabel 12,  Yudao Shen 13,  Jing Liu 13,  Jian Jin 13,  Matthew C Rhodes 14,  Richard E Taylor 14,  Henrik Molina 15,  Jedd D Wolchok 9,  Taha Merghoub 9,  Luis A Diaz Jr 5,  Omar Abdel-Wahab 16,  Robert K Bradley 17
Affiliations

Affiliations

  • 1 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
  • 2 Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA.
  • 3 Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
  • 4 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA; Center for Immunotherapy and Precision-Oncology, Cleveland Clinic, Cleveland, OH 44195, USA.
  • 5 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
  • 6 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA; Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
  • 7 Department of Epidemiology and Biostatistics, Computational Oncology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
  • 8 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
  • 9 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA; Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
  • 10 Medical Scientist Training Program, Weill Cornell Medical School, New York, NY 10065, USA.
  • 11 Center for Immunotherapy and Precision-Oncology, Cleveland Clinic, Cleveland, OH 44195, USA; The Precision Immunology Institute, The Tisch Cancer Institute, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • 12 Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA; Medical Scientist Training Program, University of Washington, Seattle, WA 98195, USA.
  • 13 Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • 14 The Warren Family Research Center for Drug Discovery and Development and the Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
  • 15 Proteomics Resource Center, The Rockefeller University, New York, NY 10065, USA.
  • 16 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA. Electronic address: [email protected].
  • 17 Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA. Electronic address: [email protected].
PMID: 34171309 DOI: 10.1016/j.cell.2021.05.038
Abstract

Although mutations in DNA are the best-studied source of neoantigens that determine response to immune checkpoint blockade, alterations in RNA splicing within Cancer cells could similarly result in neoepitope production. However, the endogenous antigenicity and clinical potential of such splicing-derived epitopes have not been tested. Here, we demonstrate that pharmacologic modulation of splicing via specific drug classes generates bona fide neoantigens and elicits anti-tumor immunity, augmenting checkpoint immunotherapy. Splicing modulation inhibited tumor growth and enhanced checkpoint blockade in a manner dependent on host T cells and Peptides presented on tumor MHC class I. Splicing modulation induced stereotyped splicing changes across tumor types, altering the MHC I-bound immunopeptidome to yield splicing-derived neoepitopes that trigger an anti-tumor T cell response in vivo. These data definitively identify splicing modulation as an untapped source of immunogenic Peptides and provide a means to enhance response to checkpoint blockade that is readily translatable to the clinic.

Keywords

PD1; PRMTs; RBM39; RNA splicing; immune checkpoint blockade; immunopeptidome; immunotherapy; neoantigens; neoepitopes; splicing.

Figures
Products